Professional Documents
Culture Documents
TSMC Revenue Breakdown - PNG
TSMC Revenue Breakdown - PNG
Story producing drugs that are used for the treatment of various types of diseases such as cancer,
heart-related, infectious, diabetes, vaccines, and many more. Merck sells its products globally but
collects its revenue mostly from 3 major regions, which are 46% US, 23% Europe – Middle East -
Africa, 20% Asia, and others.
Sales Merck’s core revenue contributor by segment is coming from Oncology products which
accounted for 44% of its 2022 revenue. This is because Mercks is well known for its cancer
medicine named KEYTRUDA which accounted for 42% of its oncology product’s revenue. Since
FVMR 2014, Mercks begin to receive its major source of revenue in the Oncology segment after gaining
approval for the KEYTRUDA medicine and is expected to gain a potential rise in revenue after
gaining a few approvals from different institutions and countries in the upcoming years.
P5F Another source of revenue comes from the Vaccines segment which is accounted for 21%. This
segment includes the making of COVID-19 vaccines, chickenpox vaccines, and the latest well-
known HPV vaccine (Gardasil) which accounted for the second top source of revenue after the
Team KEYTRUDA product. The other segments include animal health products, diabetes medicine, etc.
P5F Another source of revenue comes from the refining & chemicals segment which is accounted for
22%. It is projected that there will be an increase in this revenue segment as PetroChina has
begin its expansion program by launching a subsidiary refinery in Southern China accounted for
Team $4.52 billion and refineries product will be granted around 10 million tonnes of new export
quotas in the upcoming period starting from the half year of 2023.
Revenue breakdown, by segments 2022
WCB
Oil & Gas Marketing 52% Refining & Chemicals 22% Exploration & Production 16% Natural Gas & Pipeline 9%
ESG
Value
Risks
Sources: A. Stotz Investment Research, company data, Refinitiv 4
TSMC: A. Stotz Four Element
Fundamentals W B
Valuation W B Fundamentals: One of the top companies
FVMR in Taiwan as it has strong profitability and
(%) Dec-18 Dec-19 Dec-20 Dec-21 PTM** (x) Dec-18 Dec-19 Dec-20 Dec-21 PTM** margin. The company also known to
Operating profit margin 35.7 33.2 40.5 40.5 49.3 Price-to-sales 6.2 6.6 11.4 9.8 5.9 effectively use the assets & equity to
P5F
Recurring net margin 34.0 32.1 38.5 37.5 45.0 Price-to-earnings 18.2 20.7 29.5 26.0 13.1
generate profits.
Asset turnover 50.5 49.1 53.3 48.9 52.1 Price-to-book 3.8 4.4 8.2 7.1 4.5
Return on assets 17.2 15.8 20.5 18.3 23.5 PE-to-EPS growth (PEG) 12.9 nm 0.6 1.7 0.2 Valuation: Unattractive as it appears
Recurring return on equity 21.9 20.8 29.7 29.6 39.9 EV/EBIT 15.7 18.7 27.1 23.2 11.4 overvalued relative to other companies in
Team the Taiwan market. Although the high
multiple might driven by the good EPS
Momentum W B Risk W B
growth and high ROE, however it will be
WCB Dec- Dec- Dec- Dec- PTM* Dec- Dec- Dec- PTM*
risky to buy & sell the stock with the
current rank on the valuation.
(%) 18 19 20 21 * (x) 18 Dec-19 20 21 *
Revenue growth 5.5 3.7 25.2 18.5 42.6 Current ratio 2.8 1.4 1.8 2.2 2.2 Momentum: Moderately attractive as both
ESG Recurring EPS growth
Operating profit margin chg.
1.4 (1.9) 50.1 15.3 71.5 Net debt-to-equity (%) (31.8) (24.7) (23.2) (19.8) (23.1) fundamental momentum and price
momentum have been relatively high.
(307) (252) 731 (1) 882 Times-interest-earned 120.6 109.1 260.4 118.6 77.4
(bps)
5yr 3yr 1yr 6mth 3mth Risk: Highly unattractive as it comes with
Value Price change
6mth
8.0
3mth
6.5
1mth
(5.9)
3wk
(1.0)
1wk
(0.6) Beta 1.3 1.2 1.5 1.7 1.8 high Beta ratio that implies high volatility
stock price and debt with quicker times for
TSMC to cover its mandatory debt even
Risks though TSMC has high current ratio to
meet its short-term financial obligations.
Note: Benchmarking against 1,060 non-financial companies in Taiwan.
Sources: A. Stotz Investment Research, Refinitiv. Notes: *Bars are decile rankings of the most recent period. **Past 12 months of published data. na = not available, nm = not meaningful.
5
Valuation is based on historical prices.
TSMC: A. Stotz Four Element
Story
Story
Sales
Fundamentals
FVMR
P5F
Team
WCB
ESG
Value
Risks
Sources: A. Stotz Investment Research, Refinitiv. Notes: *Bars are decile rankings of the most recent period. **Past 12 months of published data. na = not available, nm = not meaningful.
7
Valuation is based on historical prices.
TSMC: A. Stotz Four Element
Story
Story
Sales
Fundamentals
FVMR
P5F
Team
WCB
ESG
Value
Risks
Sources: A. Stotz Investment Research, Refinitiv. Notes: *Bars are decile rankings of the most recent period. **Past 12 months of published data. na = not available, nm = not meaningful.
8
Valuation is based on historical prices.
TSMC: A. Stotz Four Element
Story
Story
Sales
Fundamentals
FVMR
P5F
Team
WCB
ESG
Value
Risks
Sources: A. Stotz Investment Research, Refinitiv. Notes: *Bars are decile rankings of the most recent period. **Past 12 months of published data. na = not available, nm = not meaningful.
9
Valuation is based on historical prices.